Skip to main content
PMC home page
Gut logoLink to Gut
. 1993;34(2 Suppl):S20–S25. doi: 10.1136/gut.34.2_suppl.s20

Diagnostic markers of viral hepatitis B and C.

C Trépo 1, F Zoulim 1, C Alonso 1, M A Petit 1, C Pichoud 1, L Vitvitski 1
PMCID: PMC1373999  PMID: 8314489

Abstract

Hepatitis B virus (HBV) serology has become extremely refined. As well as the recognised hepatitis B surface (HBs), hepatitis B core (HBc), and hepatitis B e (HBe) antigen-antibody systems, new markers have been introduced including pre-S1, pre-S2 for the envelope and the functional X protein. New automates have been introduced allowing flexibility in the different tests according to precise needs. The monitoring of pre-S1 antigen provides a relevant correlate of viral replication. The quantitative determination of HBV-DNA, pre-S1 Ag, and IgM anti-HBc seem most useful for the decision to use, and the monitoring of, antiviral treatment. Second generation ELISAs detect antibodies to three sets of hepatitis C virus (HCV) protein including the c22 core, and c33, and c100, which correspond to the non-structural regions (NS3 and NS4, respectively). Second generation ELISAs require confirmation by supplement assays, but their biggest limitation is the delayed appearance of anti-HCV after primary infection. In addition 10% of chronic infections with liver disease still remain seronegative despite circulating HCV RNA in serum or liver, or both. Much progress still has to be made before HCV serology can reach the level of sophistication of HBV.

Full text

PDF
S21

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alter H. J. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology. 1992 Feb;15(2):350–353. doi: 10.1002/hep.1840150228. [DOI] [PubMed] [Google Scholar]
  2. Boudart D., Lucas J. C., Muller J. Y., Le Carrer D., Planchon B., Harousseau J. L. False-positive hepatitis C virus antibody tests in paraproteinaemia. Lancet. 1990 Jul 7;336(8706):63–63. doi: 10.1016/0140-6736(90)91585-x. [DOI] [PubMed] [Google Scholar]
  3. Brunetto M. R., Giarin M. M., Oliveri F., Chiaberge E., Baldi M., Alfarano A., Serra A., Saracco G., Verme G., Will H. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci U S A. 1991 May 15;88(10):4186–4190. doi: 10.1073/pnas.88.10.4186. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Carman W. F., Jacyna M. R., Hadziyannis S., Karayiannis P., McGarvey M. J., Makris A., Thomas H. C. Mutation preventing formation of hepatitis B e antigen in patients with chronic hepatitis B infection. Lancet. 1989 Sep 9;2(8663):588–591. doi: 10.1016/s0140-6736(89)90713-7. [DOI] [PubMed] [Google Scholar]
  5. Feitelson M. A., Clayton M. M., Blumberg B. S. X antigen/antibody markers in hepadnavirus infections. Presence and significance of hepadnavirus X gene product(s) in serum. Gastroenterology. 1990 Apr;98(4):1071–1078. doi: 10.1016/0016-5085(90)90035-y. [DOI] [PubMed] [Google Scholar]
  6. Feitelson M. A., Millman I., Duncan G. D., Blumberg B. S. Presence of antibodies to the polymerase gene product(s) of hepatitis B and woodchuck hepatitis virus in natural and experimental infections. J Med Virol. 1988 Feb;24(2):121–136. doi: 10.1002/jmv.1890240202. [DOI] [PubMed] [Google Scholar]
  7. Gerlich W. H., Uy A., Lambrecht F., Thomssen R. Cutoff levels of immunoglobulin M antibody against viral core antigen for differentiation of acute, chronic, and past hepatitis B virus infections. J Clin Microbiol. 1986 Aug;24(2):288–293. doi: 10.1128/jcm.24.2.288-293.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Horiike N., Blumberg B. S., Feitelson M. A. Characteristics of hepatitis B X antigen, antibodies to X antigen, and antibodies to the viral polymerase during hepatitis B virus infection. J Infect Dis. 1991 Dec;164(6):1104–1112. doi: 10.1093/infdis/164.6.1104. [DOI] [PubMed] [Google Scholar]
  9. Ikeda Y., Toda G., Hashimoto N., Kurokawa K. Antibody to superoxide dismutase, autoimmune hepatitis, and antibody tests for hepatitis C virus. Lancet. 1990 Jun 2;335(8701):1345–1346. doi: 10.1016/0140-6736(90)91228-3. [DOI] [PubMed] [Google Scholar]
  10. Lenzi M., Ballardini G., Fusconi M., Cassani F., Selleri L., Volta U., Zauli D., Bianchi F. B. Type 2 autoimmune hepatitis and hepatitis C virus infection. Lancet. 1990 Feb 3;335(8684):258–259. doi: 10.1016/0140-6736(90)90070-l. [DOI] [PubMed] [Google Scholar]
  11. Levrero M., Jean-Jean O., Balsano C., Will H., Perricaudet M. Hepatitis B virus (HBV) X gene expression in human cells and anti-HBx antibodies detection in chronic HBV infection. Virology. 1990 Jan;174(1):299–304. doi: 10.1016/0042-6822(90)90079-7. [DOI] [PubMed] [Google Scholar]
  12. McFarlane I. G., Smith H. M., Johnson P. J., Bray G. P., Vergani D., Williams R. Hepatitis C virus antibodies in chronic active hepatitis: pathogenetic factor or false-positive result? Lancet. 1990 Mar 31;335(8692):754–757. doi: 10.1016/0140-6736(90)90870-b. [DOI] [PubMed] [Google Scholar]
  13. Okamoto H., Yotsumoto S., Akahane Y., Yamanaka T., Miyazaki Y., Sugai Y., Tsuda F., Tanaka T., Miyakawa Y., Mayumi M. Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol. 1990 Mar;64(3):1298–1303. doi: 10.1128/jvi.64.3.1298-1303.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Petit M. A., Zoulim F., Capel F., Dubanchet S., Dauguet C., Trepo C. Variable expression of preS1 antigen in serum during chronic hepatitis B virus infection: an accurate marker for the level of hepatitis B virus replication. Hepatology. 1990 May;11(5):809–814. doi: 10.1002/hep.1840110515. [DOI] [PubMed] [Google Scholar]
  15. Pfaff E., Salfeld J., Gmelin K., Schaller H., Theilmann L. Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. Virology. 1987 Jun;158(2):456–460. doi: 10.1016/0042-6822(87)90221-2. [DOI] [PubMed] [Google Scholar]
  16. Schultz M., Müller R., von zur Mühlen A., Brabant G. Induction of hyperthyroidism by interferon-alpha-2b. Lancet. 1989 Jun 24;1(8652):1452–1452. doi: 10.1016/s0140-6736(89)90157-8. [DOI] [PubMed] [Google Scholar]
  17. Schvarcz R., von Sydow M., Weiland O. Autoimmune chronic active hepatitis: changing reactivity for antibodies to hepatitis C virus after immunosuppressive treatment. Scand J Gastroenterol. 1990 Nov;25(11):1175–1180. doi: 10.3109/00365529008998551. [DOI] [PubMed] [Google Scholar]
  18. Schvarcz R., von Sydow M., Weiland O. Positive reactivity with anti-HCV ELISA in patients with autoimmune hepatitis--not confirmed with a neutralization test. Scand J Infect Dis. 1991;23(1):127–128. doi: 10.3109/00365549109023388. [DOI] [PubMed] [Google Scholar]
  19. Smith H. M., Lau J. Y., Davies S. E., Daniels H. M., Alexander G. J., Williams R. Significance of serum IgM anti-HBc in chronic hepatitis B virus infection. J Med Virol. 1992 Jan;36(1):16–20. doi: 10.1002/jmv.1890360104. [DOI] [PubMed] [Google Scholar]
  20. Sugitani M., Inchauspé G., Shindo M., Prince A. M. Sensitivity of serological assays to identify blood donors with hepatitis C viraemia. Lancet. 1992 Apr 25;339(8800):1018–1019. doi: 10.1016/0140-6736(92)90538-e. [DOI] [PubMed] [Google Scholar]
  21. Thiele D. L. Implications of anti-hepatitis C reactivity in 'autoimmune' chronic active hepatitis. Gastroenterology. 1990 Nov;99(5):1531–1533. doi: 10.1016/0016-5085(90)91195-c. [DOI] [PubMed] [Google Scholar]
  22. Tong S. P., Li J. S., Vitvitski L., Trépo C. Active hepatitis B virus replication in the presence of anti-HBe is associated with viral variants containing an inactive pre-C region. Virology. 1990 Jun;176(2):596–603. doi: 10.1016/0042-6822(90)90030-u. [DOI] [PubMed] [Google Scholar]
  23. Tong S. P., Li J. S., Vitvitski L., Trépo C. Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology. 1992 Nov;191(1):237–245. doi: 10.1016/0042-6822(92)90185-r. [DOI] [PubMed] [Google Scholar]
  24. Trépo C., Chemin I., Petit M. A., Chossegros P., Zoulim F., Chevallier P., Sepetjan M. Possible prevention of chronic hepatitis B by early interferon therapy. J Hepatol. 1990;11 (Suppl 1):S95–S99. doi: 10.1016/0168-8278(90)90172-n. [DOI] [PubMed] [Google Scholar]
  25. Vento S., Di Perri G., Garofano T., Cosco L., Concia E., Ferraro T., Bassetti D. Hazards of interferon therapy for HBV-seronegative chronic hepatitis. Lancet. 1989 Oct 14;2(8668):926–926. doi: 10.1016/s0140-6736(89)91595-x. [DOI] [PubMed] [Google Scholar]
  26. Vitvitski-Trépo L., Kay A., Pichoud C., Chevallier P., de Dinechin S., Shamoon B. M., Mandart E., Trépo C., Galibert F. Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology. 1990 Dec;12(6):1278–1283. doi: 10.1002/hep.1840120605. [DOI] [PubMed] [Google Scholar]
  27. Zoulim F., Mimms L., Floreani M., Pichoud C., Chemin I., Kay A., Vitvitski L., Trepo C. New assays for quantitative determination of viral markers in management of chronic hepatitis B virus infection. J Clin Microbiol. 1992 May;30(5):1111–1119. doi: 10.1128/jcm.30.5.1111-1119.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Gut are provided here courtesy of BMJ Publishing Group

RESOURCES